Notice of Meeting; Interagency Autism Coordinating Committee, 56724-56725 [05-19377]
Download as PDF
<![CDATA[
56724
Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
into the building by non-government
employees. Persons without a government
I.D. will need to show a photo I.D. and signin at the security desk upon entering the
building.
Information is also available on the
Institute’s/Center’s home page:
www.copr.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: September 21, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–19386 Filed 9–27–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting: Secretary’s
Advisory Committee on Genetics,
Health, and Society
Pursuant to Public Law 92–463,
notice is hereby given of the eighth
meeting of the Secretary’s Advisory
Committee on Genetics, Health, and
Society (SACGHS), U.S. Public Health
Service. The meeting will be held from
8:30 a.m. to 6 p.m. on October 19, 2005
and 8:30 a.m. to 5 p.m. on October 20,
2005 at the Bethesda North Marriott
Hotel, 5701 Marinelli Road, North
Bethesda, Maryland. The meeting will
be open to the public with attendance
VerDate Aug<31>2005
16:02 Sep 27, 2005
Jkt 205001
limited to space available. The meeting
will be webcast.
The first half of the meeting will be
devoted to the issue of large population
studies of genetic variation, the
environment and common disease. The
Committee is working to identify salient
scientific, ethical, and policy issues and
questions associated with such studies
and processes that could be employed to
address them. On October 19, the
Committee will gather input from
several leaders in science and bioethics
about the policy issues and how to
address them, including mechanisms for
engaging the general public. October
20th will be devoted to the further
exploration of current issues in
pharmacogenomics. The Committee is
developing a report to the Secretary on
this topic, and at this meeting they will
explore the financial and economic
considerations involved in integrating
pharmacogenomics into clinical practice
as well as delve more deeply into
certain ethical, legal and social issues
raised by pharmacogenomics. Time will
be provided each day for public
comments, and the public is encouraged
to provide its perspectives to the
committee on these topics or any others
related to the development and use of
genetic technologies.
Under authority of 42 U.S.C. 217a,
Section 222 of the Public Health Service
Act, as amended, the Department of
Health and Human Services established
SACGHS to serve as a public forum for
deliberations on the broad range of
human health and societal issues raised
by the development and use of genetic
technologies and, as warranted, to
provide advice on these issues. The
draft meeting agenda and other
information about SACGHS, including
information about access to the webcast,
will be available at the following Web
site: https://www4.od.nih.gov/oba/
sacghs.htm.
The Committee would welcome
hearing from anyone wishing to provide
public comment on any issue related to
genetics, health and society. Individuals
who would like to provide public
comment or who plan to attend the
meeting and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the SACGHS Executive
Secretary, Ms. Sarah Carr, by telephone
at (301) 496–9838 or e-mail at
sc112c@nih.gov. The SACGHS office is
located at 6705 Rockledge Drive, Suite
750, Bethesda, MD 20892.
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
Dated: September 21, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–19387 Filed 9–27–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Meeting; Interagency Autism
Coordinating Committee
The National Institutes of Health
(NIH) hereby announces a meeting of
the Interagency Autism Coordinating
Committee to be held on November 18,
2005, on the NIH campus in Bethesda,
Maryland.
The Children’s Health Act of 2000
(Pub. L. 106–310), Title I, Section 104,
mandated the establishment of an
Interagency Autism Coordinating
Committee (IACC) to coordinate autism
research and other efforts within the
Department of Health and Human
Services (HHS). In April 2001, the HHS
Secretary delegated the authority to
establish the IACC to the NIH. The
National Institute of Mental Health
(NIMH) at the NIH has been designated
the lead for this activity.
The IACC meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the contact person listed below in
advance of the meeting.
Name of Committee: Interagency Autism
Coordinating Committee.
Date: November 18, 2005.
Time: 9 a.m.–4:30 p.m.
Agenda: Discussion of autism activities
across Federal agencies.
Place: National Institutes of Health, 31
Center Drive, Building 31, Conference Room
10 (6th floor), Bethesda, Maryland 20892.
Contact Person: Ann Wagner, Ph.D.,
Division of Services and Intervention
Research, National Institute of Mental Health,
NIH, 6001 Executive Boulevard, Room 6184,
MSC 9617, Bethesda, Maryland 20892, Email: awagner@mail.nih.gov, Phone: (301)
443–5944.
Any member of the public interested in
presenting oral comments to the Committee
may notify the contact person listed on this
notice at least 5 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation.
Presentations may be limited to 5 minutes;
both printed and electronic copies are
requested for the record. In addition, any
interested person may file written comments
E:\FR\FM\28SEN1.SGM
28SEN1
Federal Register / Vol. 70, No. 187 / Wednesday, September 28, 2005 / Notices
with the Committee by forwarding his/her
statement to the contact person listed on this
notice. The statement should include the
name, address, telephone number, and, when
applicable, the business or professional
affiliation of the interested person.
Information about the meeting and online
registration forms are also available online on
the NIMH homepage at https://
www.nimh.nih.gov/autismiacc/index.cfm.
Dated: September 21, 2005.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 05–19377 Filed 9–27–05; 8:45 am]
Dated: September 21, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–19382 Filed 9–27–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Closed Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (U.S.C. Appendix 2), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, SBIR
Topics 200 (Phase II) and 201 (Phase II),
Date: October 19, 2005.
Time: 12 p.m. to 2 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6130
Executive Blvd., Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Joyce C. Pegues, PhD,
Scientific Review Administrator, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, 6116 Executive Blvd., 7149,
Bethesda, MD 20892, 301/594–1286,
peguesj@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
VerDate Aug<31>2005
16:02 Sep 27, 2005
Jkt 205001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(C)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Nursing Research Initial Review Group.
Date: October 20–21, 2005.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Jeffrey M. Chernak, PhD.,
Scientific Review Administrator, Office of
Review, National Institute of Nursing
Research, 6701 Democracy Plaza, Suite 712,
MSC 4870, Bethesda, MD 20817; (301) 402–
6959, chernak@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.361, Nursing Research,
National Institutes of Health, HHS)
Dated: September 21, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–19380 Filed 9–27–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
56725
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Initial Review Group,
Medication Development Research
Subcommittee.
Date: October 5, 2005.
Time: 8:30 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Paul A. Coulis, PhD,
Health Scientist Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6101 Executive Boulevard, Suite 220,
Bethesda, MD 20892–8401, 301–443–2105.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Initial Review Group, Health
Services Research Subcommittee.
Date: October 6–7, 2005.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Gerald L. McLaughlin,
PhD, Scientific Review Administrator, Office
of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS Room 220, MSC
8401, 6101 Executive Blvd., Bethesda, MD
20892–8401, 301–402–6626, gm145@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Initial Review Group, Treatment
Research Subcommittee.
Date: October 6–7, 2005.
Time: 9 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Kesinee Nimit, MD, Health
Scientist Administrator, Office of Extramural
Affairs, National Institute on Drug Abuse,
NIH, DHHS Room 220, MSC 8401, 6101
Executive Boulevard, Bethesda, MD 20892–
8401, 301–435–1432.
This notice is being published less than 15
days prior to the meeting due to the timing
E:\FR\FM\28SEN1.SGM
28SEN1
]]>Agencies
[Federal Register Volume 70, Number 187 (Wednesday, September 28, 2005)]
[Notices]
[Pages 56724-56725]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-19377]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Meeting; Interagency Autism Coordinating Committee
The National Institutes of Health (NIH) hereby announces a meeting
of the Interagency Autism Coordinating Committee to be held on November
18, 2005, on the NIH campus in Bethesda, Maryland.
The Children's Health Act of 2000 (Pub. L. 106-310), Title I,
Section 104, mandated the establishment of an Interagency Autism
Coordinating Committee (IACC) to coordinate autism research and other
efforts within the Department of Health and Human Services (HHS). In
April 2001, the HHS Secretary delegated the authority to establish the
IACC to the NIH. The National Institute of Mental Health (NIMH) at the
NIH has been designated the lead for this activity.
The IACC meeting will be open to the public, with attendance
limited to space available. Individuals who plan to attend and need
special assistance, such as sign language interpretation or other
reasonable accommodations, should notify the contact person listed
below in advance of the meeting.
Name of Committee: Interagency Autism Coordinating Committee.
Date: November 18, 2005.
Time: 9 a.m.-4:30 p.m.
Agenda: Discussion of autism activities across Federal agencies.
Place: National Institutes of Health, 31 Center Drive, Building
31, Conference Room 10 (6th floor), Bethesda, Maryland 20892.
Contact Person: Ann Wagner, Ph.D., Division of Services and
Intervention Research, National Institute of Mental Health, NIH,
6001 Executive Boulevard, Room 6184, MSC 9617, Bethesda, Maryland
20892, E-mail: awagner@mail.nih.gov, Phone: (301) 443-5944.
Any member of the public interested in presenting oral comments
to the Committee may notify the contact person listed on this notice
at least 5 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Presentations may be limited
to 5 minutes; both printed and electronic copies are requested for
the record. In addition, any interested person may file written
comments
[[Page 56725]]
with the Committee by forwarding his/her statement to the contact
person listed on this notice. The statement should include the name,
address, telephone number, and, when applicable, the business or
professional affiliation of the interested person.
Information about the meeting and online registration forms are
also available online on the NIMH homepage at https://
www.nimh.nih.gov/autismiacc/index.cfm.
Dated: September 21, 2005.
Raynard S. Kington,
Deputy Director, National Institutes of Health.
[FR Doc. 05-19377 Filed 9-27-05; 8:45 am]
BILLING CODE 4140-01-P
